Abstract
Carbamazepine (CBZ) clearance decreases from childhood to adulthood and the factors determining this change could include age, size, autoinduction, or maturational changes. This study aims to describe the population pharmacokinetics of CBZ in children and young adults and test the hypothesis that CBZ clearance correlates with weight, surface area, and age. CBZ therapeutic drug monitoring data (sparse data) were collected from child and adult epileptics, and rich data were obtained from a bioequivalence study of CBZ in young adults. Population pharmacokinetic analysis was performed using NONMEM V. Forward stepwise, multiple regression was performed on the covariates. Bootstrap validation was performed. A total of 946 observations from 91 subjects, ages 0.7–37 years, were collected and analyzed. A one-compartment, first-order absorption and elimination model, with exponential interindividual error and additive residual error models was developed. The population model was: Clearance (Lhr −1)=((2.24 · Surface area (m 2))+(0.047 · Dose (mg · kg −1)); Volume of distribution (L)=0.37 · weight (kg); Absorption rate constant=0.013 (hr −1). CBZ clearance increased with surface area and dose.
Similar content being viewed by others
REFERENCES
R. H. Levy, W. H. Pitlick, A. S. Troupin, J. R. Green, and J. M. Neal. Pharmacokinetics of carbamazepine in normal man. Clin. Pharmacol. Ther. 17:657–668 (1975).
N. H. G. Holford. A size standard for pharmacokinetics. Clin. Pharmacokin. 30:329–332 (1996).
M. F. D. Iribarnegaray, D. S. Buelga, M. J. S. Sánchez, M. J. Otero, A. C. Falcaõ, and A. Domínguez-Gil. Carbamazepine population pharmacokinetics in children: mixed-effect models. Ther. Drug. Monit. 19:132–139 (1997).
E. Yukawa and T. Aoyama. Detection of carbamazepine drug interaction by multiple peak approach screening using routine clinical pharmacokinetic data. J. Clin. Pharmacol. 36:752–759 (1996).
A. L. Gray, J. H. Botha, and R. Miller. A model for the determination of carbamazepine clearance in children on mono-and poly-therapy. Eur. J. Clin. Pharmacol. 54:359–362 (1998).
L. Sheiner and S. L. Beal. NONMEM V ed., NONMEM Project Group, San Francisco, 1994.
Microsoft. Fortran PowerStation 4.0, Microsoft Corporation, 1995.
Microsoft. Excel SR-1, Microsoft Corporation, 1997.
MathSoft. Axum 5.0B for Windows, MathSoft Inc., 1996.
Stata Corporation. STATA for Windows 4.0 ed., Stata Corporation, College Station, TX77840, 1995.
A. Boeckmann, L. Scheiner, and S. Beal. NONMEM Users Guide--Part V, University of California at San Francisco, 1994.
R. D. Mosteller. Simplified calculation of body-surface area. New Engl. J. Med. 1098 (1987).
B. Sheiner. Analysis of pharmacokinetic data using parametric models. III. Hypothesis tests and confidence intervals. J. Pharmacokinet. Biopharm. 14:539–555 (1986).
J. Parke, N. H. G. Holford, and B. G. Charles. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput. Meth. Prog. Biomed. 59:19–20 (1999).
J. A. Lack and M. E. Stuart-Taylor. Calculation of drug dosage and body surface area of children. Br. J. Anaesth. 78:601–605 (1997).
K. Urata, S. Kawasaki, H. Matsunami, Y. Hashikura, T. Ikegami, S. Ishizone, Y. Momose, A. Komiyama, and M. Makuuchi. Calculation of child and adult standard liver volume for liver transplantation. Hepatology 21:1317–1321 (1995).
J. Carles, J. El Kohen, D. Midy, J. Saric, and J. Videau. Appréciation du volume hépatique en fonction de la morphologie de l'individu. Bull. Assoc. Anatom. 77:9–13 (1993).
F. H. DeLand and W. A. North. Relationship between liver size and body size. Radiology 91:1195–1198 (1968).
N. M. Graves, R. C. Brundage, Y. Wen, G. Cascino, E. So, P. Ahman, J. Rarick, S. Krause, and I. E. Leppik. Population pharmacokinetics of carbamazepine in adults with epilepsy. Pharmacotherapy 18:273–281 (1998).
L. Z. Benet and R. L. Williams. Appendix II. Design and optimization of dosage regimens: pharmacokinetic data. In A. G. Gilman, T. W. Rall, A. S. Nies, and A. S. Taylor (eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics. International ed., 8th ed. McGraw-Hill, Singapore, 1991, pp. 1650–1736.
H. F. Hvidberg and M. Dam. Clinical pharmacokinetics of anticonvulsants. Clin. Pharmacokin. 1:161–188 (1976).
T. Tomson, J. O. Svensson, and P. Hilton-Brown. Relationship of intraindividual dose–plasma concentration of carbamazepine: indication of dose-dependent induction of metabolism. Ther. Drug Monit. 11:533–539 (1989).
D. A. Graves, C. S. Locke, K. T. Muir, and R. P. Miller. The influence of assay variability on pharmacokinetic parameter estimation. J. Pharmacokin. Biopharm. 17: 571–592 (1989).
H. Sun, E. I. Ette, and T. M. Ludden. On the recording of sample times and parameter estimation from repeated measures pharmacokinetic data. J. Pharmacokin. Biopharm. 24:637–650 (1996).
D. B. White, C. A. Walawander, D. Y. Liu, and T. H. Grasela. Evaluation of hypothesis testing for comparing two populations using NONMEM analysis. J. Pharmacokin. Biopharm. 20:295–313 (1992).
M. K. Al-Banna, A. W. Kelman, and B. Whiting. Experimental design and efficient parameter estimation in population pharmacokinetics. J. Pharmacokin. Biopharm. 18:347–360 (1990).
E. I. Ette. Stability and performance of a population pharmacokinetic model. J. Clin. Pharmacol. 37:486–495 (1997).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Reith, D.M., Hooper, W.D., Parke, J. et al. Population Pharmacokinetic Modeling of Steady State Carbamazepine Clearance in Children, Adolescents, and Adults. J Pharmacokinet Pharmacodyn 28, 79–92 (2001). https://doi.org/10.1023/A:1011569703060
Issue Date:
DOI: https://doi.org/10.1023/A:1011569703060